September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Results for Durvalumab in the Second-Line Treatment of NSCLC
July 13th 2017Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.
Watch
Nivolumab With Ipilimumab for Small Cell Lung Cancer
July 6th 2017Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study, which explored nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
Watch
Dabrafenib/Trametinib Combo Approved by FDA for BRAF+ NSCLC
June 23rd 2017The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has been approved by the FDA for the treatment of patients with <em>BRAF</em> V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
Read More
Dacomitinib Superior Over Gefitinib in EGFR-Mutant NSCLC
June 21st 2017The risk of disease progression was reduced by more than 40% and there was an average 6.5-month improvement in response duration with the second-generation EGFR inhibitor dacomitinib compared with gefitinib as a first-line treatment for patients with advanced, <em>EGFR</em>-mutant non–small cell lung cancer.
Read More
First-Line Carboplatin and Pemetrexed With Pembrolizumab for NSCLC
June 21st 2017Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses first-line carboplatin and pemetrexed with or without pembrolizumab for advanced nonsquamous non–small cell lung cancer.
Watch
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC
June 19th 2017Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.
Watch
Alectinib Improved PFS by 15 Months Over Crizotinib in ALK+ NSCLC in ALEX Trial
June 5th 2017Second-generation ALK inhibitor alectinib (Alecensa) demonstrated a 15-month improvement in progression-free survival compared with crizotinib (Xalkori), the first-generation ALK inhibitor and standard of care, in patients with <em>ALK</em>-positive non–small cell lung cancer.
Read More
Updates to NSCLC Guidelines Make Testing at Diagnosis, Resistance Essential
May 30th 2017Updates to the NCCN guidelines for the management of advanced NSCLC stress the importance of multiplexed biomarker testing at diagnosis to aid in the selection of appropriate first-line and subsequent lines of therapy.
Read More